Coherus Inventory vs Accounts Payable Analysis

CHRS Stock

USD 0.88 0.03 3.53%

Coherus BioSciences financial indicator trend analysis is way more than just evaluating Coherus BioSciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Coherus BioSciences is a good investment. Please check the relationship between Coherus BioSciences Inventory and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.

Inventory vs Accounts Payable

Inventory vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Coherus BioSciences Inventory account and Accounts Payable. At this time, the significance of the direction appears to have very week relationship.

The correlation between Coherus BioSciences' Inventory and Accounts Payable is 0.23. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Coherus BioSciences, assuming nothing else is changed. The correlation between historical values of Coherus BioSciences' Inventory and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Coherus BioSciences are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Inventory i.e., Coherus BioSciences' Inventory and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.23

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Inventory

Accounts Payable

An accounting item on the balance sheet that represents Coherus BioSciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Coherus BioSciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Coherus BioSciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Coherus BioSciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.Selling General Administrative is likely to drop to about 100.1 M in 2024. Tax Provision is likely to gain to about (361 K) in 2024

	2021	2022	2023	2024 (projected)
Interest Expense	23.0M	32.5M	40.5M	42.6M
Depreciation And Amortization	5.7M	3.7M	3.8M	2.0M

Interest Expense Depreciation And Amortization

Coherus BioSciences fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Common Stock Shares Outstanding		0.83	0.86	0.51	0.49	-0.04	0.01	0.76	-0.4	0.46	-0.88	0.67	0.55	0.59	0.61	0.78	0.63	0.7	0.96	0.33	0.88	0.74	0.72	0.98	0.77	0.9
Total Assets	0.83		0.93	0.49	0.47	0.22	0.34	0.72	-0.32	0.29	-0.68	0.51	0.81	0.55	0.58	0.84	0.88	0.76	0.77	0.25	0.93	0.86	0.83	0.8	0.82	0.88
Short Long Term Debt Total	0.86	0.93		0.55	0.52	-0.1	0.16	0.58	-0.37	0.56	-0.82	0.51	0.58	0.65	0.72	0.88	0.7	0.78	0.84	0.52	0.98	0.9	0.86	0.87	0.89	0.96
Other Current Liab	0.51	0.49	0.55		0.97	-0.52	-0.22	0.33	-0.35	0.73	-0.74	0.55	0.16	0.92	0.77	0.79	0.18	0.91	0.49	0.1	0.48	0.37	0.84	0.51	0.83	0.49
Total Current Liabilities	0.49	0.47	0.52	0.97		-0.53	-0.08	0.36	-0.14	0.66	-0.72	0.65	0.17	0.94	0.82	0.74	0.18	0.87	0.49	0.07	0.48	0.3	0.81	0.49	0.82	0.49
Total Stockholder Equity	-0.04	0.22	-0.1	-0.52	-0.53		0.46	0.34	0.04	-0.79	0.41	-0.18	0.63	-0.53	-0.49	-0.22	0.54	-0.28	-0.1	-0.44	-0.03	0.06	-0.27	-0.1	-0.32	-0.11
Other Liab	0.01	0.34	0.16	-0.22	-0.08	0.46		0.15	0.62	-0.52	0.16	0.15	0.61	-0.07	0.08	-0.05	0.57	-0.07	-0.02	-0.22	0.24	0.09	0.06	-0.03	0.07	0.11
Property Plant And Equipment Net	0.76	0.72	0.58	0.33	0.36	0.34	0.15		-0.12	0.06	-0.57	0.67	0.68	0.45	0.46	0.57	0.7	0.53	0.74	0.04	0.65	0.48	0.48	0.72	0.53	0.66
Current Deferred Revenue	-0.4	-0.32	-0.37	-0.35	-0.14	0.04	0.62	-0.12		-0.49	0.42	0.16	-0.12	-0.16	-0.05	-0.49	-0.16	-0.44	-0.35	-0.21	-0.29	-0.52	-0.41	-0.43	-0.35	-0.33
Net Debt	0.46	0.29	0.56	0.73	0.66	-0.79	-0.52	0.06	-0.49		-0.75	0.25	-0.22	0.72	0.66	0.71	-0.08	0.69	0.48	0.66	0.49	0.49	0.69	0.52	0.71	0.55
Retained Earnings	-0.88	-0.68	-0.82	-0.74	-0.72	0.41	0.16	-0.57	0.42	-0.75		-0.64	-0.32	-0.82	-0.82	-0.85	-0.42	-0.81	-0.91	-0.45	-0.81	-0.66	-0.82	-0.92	-0.89	-0.85
Accounts Payable	0.67	0.51	0.51	0.55	0.65	-0.18	0.15	0.67	0.16	0.25	-0.64		0.29	0.68	0.69	0.47	0.29	0.54	0.72	-0.03	0.56	0.23	0.47	0.66	0.55	0.59
Cash	0.55	0.81	0.58	0.16	0.17	0.63	0.61	0.68	-0.12	-0.22	-0.32	0.29		0.23	0.28	0.48	0.98	0.43	0.47	-0.16	0.62	0.56	0.5	0.5	0.49	0.53
Non Current Assets Total	0.59	0.55	0.65	0.92	0.94	-0.53	-0.07	0.45	-0.16	0.72	-0.82	0.68	0.23		0.95	0.78	0.28	0.85	0.63	0.24	0.61	0.39	0.83	0.61	0.88	0.63
Non Currrent Assets Other	0.61	0.58	0.72	0.77	0.82	-0.49	0.08	0.46	-0.05	0.66	-0.82	0.69	0.28	0.95		0.73	0.36	0.75	0.68	0.38	0.69	0.43	0.78	0.65	0.86	0.71
Other Assets	0.78	0.84	0.88	0.79	0.74	-0.22	-0.05	0.57	-0.49	0.71	-0.85	0.47	0.48	0.78	0.73		0.58	0.96	0.73	0.45	0.86	0.85	0.97	0.78	0.96	0.84
Cash And Short Term Investments	0.63	0.88	0.7	0.18	0.18	0.54	0.57	0.7	-0.16	-0.08	-0.42	0.29	0.98	0.28	0.36	0.58		0.48	0.56	0.07	0.74	0.69	0.58	0.59	0.58	0.66
Net Receivables	0.7	0.76	0.78	0.91	0.87	-0.28	-0.07	0.53	-0.44	0.69	-0.81	0.54	0.43	0.85	0.75	0.96	0.48		0.65	0.25	0.74	0.69	0.96	0.69	0.94	0.72
Common Stock Total Equity	0.96	0.77	0.84	0.49	0.49	-0.1	-0.02	0.74	-0.35	0.48	-0.91	0.72	0.47	0.63	0.68	0.73	0.56	0.65		0.37	0.86	0.66	0.66	0.98	0.74	0.89
Short Term Investments	0.33	0.25	0.52	0.1	0.07	-0.44	-0.22	0.04	-0.21	0.66	-0.45	-0.03	-0.16	0.24	0.38	0.45	0.07	0.25	0.37		0.52	0.58	0.36	0.38	0.41	0.55
Non Current Liabilities Total	0.88	0.93	0.98	0.48	0.48	-0.03	0.24	0.65	-0.29	0.49	-0.81	0.56	0.62	0.61	0.69	0.86	0.74	0.74	0.86	0.52		0.9	0.83	0.88	0.86	0.98
Inventory	0.74	0.86	0.9	0.37	0.3	0.06	0.09	0.48	-0.52	0.49	-0.66	0.23	0.56	0.39	0.43	0.85	0.69	0.69	0.66	0.58	0.9		0.77	0.74	0.76	0.87
Other Current Assets	0.72	0.83	0.86	0.84	0.81	-0.27	0.06	0.48	-0.41	0.69	-0.82	0.47	0.5	0.83	0.78	0.97	0.58	0.96	0.66	0.36	0.83	0.77		0.71	0.98	0.8
Other Stockholder Equity	0.98	0.8	0.87	0.51	0.49	-0.1	-0.03	0.72	-0.43	0.52	-0.92	0.66	0.5	0.61	0.65	0.78	0.59	0.69	0.98	0.38	0.88	0.74	0.71		0.78	0.92
Total Liab	0.77	0.82	0.89	0.83	0.82	-0.32	0.07	0.53	-0.35	0.71	-0.89	0.55	0.49	0.88	0.86	0.96	0.58	0.94	0.74	0.41	0.86	0.76	0.98	0.78		0.85
Property Plant And Equipment Gross	0.9	0.88	0.96	0.49	0.49	-0.11	0.11	0.66	-0.33	0.55	-0.85	0.59	0.53	0.63	0.71	0.84	0.66	0.72	0.89	0.55	0.98	0.87	0.8	0.92	0.85

Click cells to compare fundamentals

Coherus BioSciences Account Relationship Matchups

Coherus BioSciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	73.2M	83.5M	75.4M	77.6M	94.2M	54.8M
Total Assets	408.9M	841.6M	679.3M	480.8M	629.6M	362.5M
Short Long Term Debt Total	180.6M	404.0M	408.3M	471.1M	480.8M	248.2M
Other Current Liab	89.0M	66.3M	59.4M	38.6M	294.4M	309.1M
Total Current Liabilities	115.0M	81.5M	79.0M	54.5M	331.8M	348.4M
Total Stockholder Equity	105.2M	281.0M	97.7M	(137.4M)	(193.4M)	(183.8M)
Other Liab	102K	75.1M	94.3M	3.5M	4.0M	3.8M
Property Plant And Equipment Net	16.5M	20.1M	7.8M	8.8M	11.0M	10.3M
Net Debt	718K	(137.1M)	(8.9M)	407.5M	378.0M	396.8M
Retained Earnings	(895.0M)	(762.8M)	(1.0B)	(1.3B)	(1.6B)	(1.5B)
Accounts Payable	26.0M	15.2M	16.2M	11.5M	35.2M	18.7M
Cash	177.7M	541.2M	417.2M	63.5M	102.9M	182.4M
Non Current Assets Total	34.2M	51.3M	45.9M	64.2M	154.0M	161.7M
Non Currrent Assets Other	14.1M	27.6M	34.5M	49.5M	70.8M	74.4M
Other Assets	45.9M	60.5M	45.9M	64.2M	73.8M	77.5M
Cash And Short Term Investments	177.7M	541.2M	417.2M	191.7M	117.7M	195.5M
Net Receivables	142.0M	157.0M	123.0M	110.0M	260.5M	273.5M
Liabilities And Stockholders Equity	408.9M	841.6M	679.3M	480.8M	629.6M	362.5M
Non Current Liabilities Total	303.7M	479.1M	502.6M	563.8M	491.3M	288.9M
Inventory	55.1M	92.2M	93.3M	115.1M	62.6M	41.2M
Other Current Assets	13.5M	25.0M	24.5M	22.9M	34.8M	36.5M
Other Stockholder Equity	1.0B	1.0B	1.1B	1.2B	1.4B	785.7M
Total Liab	303.7M	560.7M	581.6M	618.3M	823.0M	864.2M
Property Plant And Equipment Gross	16.5M	20.1M	24.7M	28.9M	25.8M	15.1M
Total Current Assets	374.7M	790.4M	633.5M	416.7M	475.6M	311.1M
Accumulated Other Comprehensive Income	(282K)	(558K)	(270K)	(249K)	(248K)	(260.4K)
Property Plant Equipment	16.5M	48.0M	63.4M	85.0M	97.8M	102.7M
Net Tangible Assets	101.7M	277.4M	97.7M	(143.3M)	(164.9M)	(156.6M)
Long Term Debt	178.4M	377.4M	408.3M	225.6M	473.4M	497.0M
Retained Earnings Total Equity	(895.0M)	(762.8M)	(1.0B)	(1.3B)	(1.2B)	(1.1B)
Capital Surpluse	1.0B	1.0B	1.1B	1.2B	1.4B	900.6M
Non Current Liabilities Other	102K	37.6M	94.3M	254.0M	11.5M	10.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Coherus Stock Analysis

When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC